中文

贝达药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-23
ItemAmountY/Y
Revenue¥1.04B+13.3%
Gross profit¥0.82B
Operating income¥0.28B
Net income¥0.23B+142.1%
Gross margin79.1%Net margin 22.2%
Revenue Q/Q+16.6%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.22B20.9%
R&D¥0.10B9.4%
SG&A¥0.42B40.7%
Tax & other¥0.05B5.0%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

佳发教育中富通汇金科技乐心医疗神宇股份筑博设计科信技术激智科技精测电子星源材质天能重工太辰光

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies